保留胰腺实质的胰腺切除术治疗胰腺实性假乳头状肿瘤:倾向性匹配分析
该回顾性研究纳入2002年6月至2024年8月单中心261例胰腺实性假乳头状肿瘤切除患者,倾向性匹配后比较保留胰腺实质的胰腺切除术与传统切除术。结果显示保留实质手术失血量更少、手术时间和住院时间更短,但总体并发症率更高(主要为术后胰瘘),无复发生存期等效。
要点
- 保留实质胰腺切除术可减少失血量、缩短手术时间和住院时间。
- 总体并发症率较高(60.0% vs 36.7%),主要由术后胰瘘驱动。
- 无复发生存期与传统切除等效,肿瘤学控制相当。
核心结论
- 对于胰腺实性假乳头状肿瘤,保留胰腺实质的胰腺切除术与传统切除术相比肿瘤学控制等效且围术期效率更优。
- 保留实质手术的术后胰瘘发生率更高但可控。
- 在经验丰富术者严格选择的患者中,保留实质胰腺切除术是可行策略。
研究设计与样本
- 回顾性研究,纳入2002年6月至2024年8月单中心261例接受胰腺实性假乳头状肿瘤切除的患者。
- 采用1:1倾向性评分匹配平衡基线特征,匹配后分析60对。
主要发现
- 匹配后保留实质组失血量更少(100 vs 200 mL,P < .001),手术时间更短(3.0 vs 5.0小时,P < .001),住院时间更短(9 vs 10.5天,P = .008)。
- 保留实质组总体并发症率更高(60.0% vs 36.7%,P = .011),主要由术后胰瘘驱动。
- 两组无复发生存期等效(P = .971),切除类型未预测复发。
- 新发糖尿病(5.2% vs 12.7%,P = .279)和胰腺外分泌功能不全(10.3% vs 16.4%,P = .346)在保留实质组数值更低但无统计学差异。
临床怎么用
- 在经验丰富术者严格选择的胰腺实性假乳头状肿瘤患者中,可考虑保留胰腺实质的胰腺切除术以缩短手术时间和住院时间。
- 需权衡保留实质手术较高的术后胰瘘风险,做好围术期管理。
- 保留实质手术可能有利于保留内分泌和外分泌功能,但需进一步证据。
局限性
- 回顾性单中心研究设计。
- 匹配后样本量较小(60对),可能影响统计效能。
- 内分泌和外分泌功能获益未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The oncological equivalence of parenchyma-sparing pancreatectomy versus conventional resection for solid pseudopapillary neoplasm of the pancreas remains debated. This study compares perioperative and long-term outcomes between these approaches. MATERIALS AND METHODS: A retrospective study was conducted on patients undergoing solid pseudopapillary neoplasm resection at a high-volume center between June 2002 and August 2024. Propensity score matching (1:1) balanced baseline characteristics between groups. Outcomes included morbidity, recurrence-free survival, and metabolic sequelae. RESULTS: Among 261 patients, 49 (18.8%) had enucleations, 28 (10.7%) had central pancreatectomies, 2 (0.8%) had duodenum-preserving pancreatic head resections, and 182 (69.7%) underwent conventional resection. After propensity score matching, 60 pairs were analyzed. Parenchyma-sparing pancreatectomy demonstrated reduced blood loss (100 vs 200 mL, P < .001), shorter operative time (3.0 vs 5.0 hours, P < .001), and shorter hospital stay (9 vs 10.5 days, P = .008). However, parenchyma-sparing pancreatectomy had a higher overall complication rate (60.0% vs 36.7%, P = .011), driven primarily by postoperative pancreatic fistula. Long-term recurrence-free survival was equivalent between groups (P = .971), with resection type not predicting recurrence. Although not statistically significant, parenchyma-sparing pancreatectomy showed numerically lower rates of new-onset diabetes mellitus (5.2% vs 12.7%, P = .279) and pancreatic exocrine insufficiency (10.3% vs 16.4%, P = .346). CONCLUSION: Parenchyma-sparing pancreatectomy for solid pseudopapillary neoplasm offers equivalent oncological control and superior perioperative efficiency compared with conventional resection, albeit with a higher incidence of manageable postoperative pancreatic fistula. Given the potential for preserved endocrine/exocrine function, parenchyma-sparing pancreatectomy is a viable strategy for carefully selected patients when performed by experienced surgeons.
引用
- Xu Y, Ji Y, Shi H, et al. Parenchyma-sparing pancreatectomy for solid pseudopapillary neoplasm of the pancreas: A propensity-matched analysis. Surgery. 2026. PMID: 42561640. doi:10.1016/j.surg.2026.110450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。